English  |  正體中文  |  简体中文  |  总笔数 :0  
造访人次 :  52947796    在线人数 :  859
教育部委托研究计画      计画执行:国立台湾大学图书馆
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
关于TAIR

浏览

消息

著作权

相关连结

"yu yun shao"的相关文件

回到依作者浏览
依题名排序 依日期排序

显示项目 41-65 / 113 (共5页)
<< < 1 2 3 4 5 > >>
每页显示[10|25|50]项目

机构 日期 题名 作者
臺大學術典藏 2020-04-10T12:16:12Z Increasing incidence of brain metastasis in patients with advanced Hepatocellular carcinoma in the era of Antiangiogenic targeted therapy YU-YUN SHAO; Lu L.-C.; Cheng A.-L.; Hsu C.-H.
臺大學術典藏 2020-04-10T12:16:12Z Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma YU-YUN SHAO; Chen P.-J.; Lin Z.-Z.; Huang C.-C.; Ding Y.-H.; Lee Y.-H.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2020-04-10T12:16:11Z Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma Shau W.-Y.; YU-YUN SHAO; Yeh Y.-C.; Lin Z.-Z.; Kuo R.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lai M.-S.
臺大學術典藏 2020-04-10T12:16:11Z Survival of patients with small cell lung carcinoma in Taiwan Kuo Y.-H.; Lin Z.-Z.; Yang Y.-Y.; YU-YUN SHAO; Shau W.-Y.; Kuo R.N.C.; Yang J.C.-H.; Lai M.-S.
臺大學術典藏 2020-04-10T12:16:10Z Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems YU-YUN SHAO; Lu L.-C.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2020-04-10T12:16:10Z Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: An East Asian population-based study Lin Z.-Z.; Shau W.-Y.; YU-YUN SHAO; Yang Y.-Y.; Kuo R.N.-C.; Yang J.C.-H.; Laie M.-S.
臺大學術典藏 2020-04-10T12:16:10Z Dissimilar immunohistochemical expression of ERK and AKT between paired biopsy and hepatectomy tissues of hepatocellular carcinoma Cheng A.-L.; YU-YUN SHAO; Chen C.-L.; Ho M.-C.; Huang C.-C.; Tu H.-C.; Hsu C.-H.
臺大學術典藏 2020-04-10T12:16:10Z Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer Yeh K.-H.; Cheng A.-L.; Lin Y.-L.; Hsu C.; Cheng W.-F.; Hsu C.-H.; YU-YUN SHAO; Lu L.-C.
臺大學術典藏 2020-04-10T12:16:10Z Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy YU-YUN SHAO; Huang C.-C.; Lin S.-D.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2020-04-10T12:16:09Z Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study Hsu C.; Cheng A.-L.; Jin K.; Hsu C.-H.; Kang Y.K.; Yang T.-S.; Shun C.-T.; YU-YUN SHAO; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.
臺大學術典藏 2020-04-10T12:16:09Z Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma Kuo R.N.C.; Lin Z.-Z.; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; Cheng A.-L.; Lai M.-S.; Lu L.-C.; YU-YUN SHAO
臺大學術典藏 2020-04-10T12:16:09Z Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer YU-YUN SHAO; Shau W.-Y.; Lin Z.-Z.; Chen H.-M.; Kuo R.; Yang J.C.-H.; Lai M.-S.
臺大學術典藏 2020-04-10T12:16:09Z The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma Chang Y.-L.; YU-YUN SHAO; Huang C.-Y.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2020-04-10T12:16:08Z β-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma Cheng A.-L.; Hsu C.-H.; Lu L.-C.;Yu-Yun Shao;Lee Y.-H.;Hsieh M.-S.;Hsiao C.-H.;Lin H.-H.;Kao H.-F.;Ma Y.-Y.;Yen F.-C.;Cheng A.-L.;Hsu C.-H.; Lu L.-C.; YU-YUN SHAO; Lee Y.-H.; Hsieh M.-S.; Hsiao C.-H.; Lin H.-H.; Kao H.-F.; Ma Y.-Y.; Yen F.-C.
臺大學術典藏 2020-04-10T12:16:08Z Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size Lin Z.-Z.; Shau W.-Y.; Hsu C.; YU-YUN SHAO; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S.
臺大學術典藏 2020-04-10T12:16:07Z Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy Lu L.-C.;Yu-Yun Shao;Chan S.-Y.;Hsu C.-H.;Cheng A.-L.; Lu L.-C.; YU-YUN SHAO; Chan S.-Y.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2020-04-10T12:16:07Z Type 2 diabetes mellitus is associated with increased mortality in chinese patients receiving curative surgery for colon cancer Chen K.-H.;Yu-Yun Shao;Lin Z.-Z.;Yeh Y.-C.;Wen-Yi S.;Kuo R.N.;Chen H.-M.;Lai C.-L.;Yeh K.-H.;Cheng A.-L.;Lai M.-S.; Chen K.-H.; YU-YUN SHAO; Lin Z.-Z.; Yeh Y.-C.; Wen-Yi S.; Kuo R.N.; Chen H.-M.; Lai C.-L.; Yeh K.-H.; Cheng A.-L.; Lai M.-S.
臺大學術典藏 2020-04-10T12:16:07Z Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastases Yu-Yun Shao;Ho M.-C.;Cheng A.-L.;Hsu C.-H.; YU-YUN SHAO; Ho M.-C.; Cheng A.-L.; Hsu C.-H.
臺大學術典藏 2020-04-10T12:16:06Z Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy Yen F.-C.; Hsu C.-H.; Cheng A.-L.; YU-YUN SHAO; Wu C.-H.; Lu L.-C.; Chan S.-Y.; Ma Y.-Y.; Yu-Yun Shao;Wu C.-H.;Lu L.-C.;Chan S.-Y.;Ma Y.-Y.;Yen F.-C.;Hsu C.-H.;Cheng A.-L.
臺大學術典藏 2020-04-10T12:16:04Z Young patients with colorectal cancer have increased risk of second primary cancers Liang Y.-H.;Yu-Yun Shao;Chen H.-M.;Lai C.-L.;Lin Z.-Z.;Kuo R.N.;Cheng A.-L.;Yeh K.-H.;Lai M.-S.; Liang Y.-H.; YU-YUN SHAO; Chen H.-M.; Lai C.-L.; Lin Z.-Z.; Kuo R.N.; Cheng A.-L.; Yeh K.-H.; Lai M.-S.
臺大學術典藏 2020-04-10T12:16:04Z Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma Liao B.-C.;Yu-Yun Shao;Chen H.-M.;Shau W.-Y.;Lin Z.-Z.;Kuo R.N.;Lai C.-L.;Chen K.-H.;Cheng A.-L.;Yang J.C.-H.;Lai M.-S.; Liao B.-C.; YU-YUN SHAO; Chen H.-M.; Shau W.-Y.; Lin Z.-Z.; Kuo R.N.; Lai C.-L.; Chen K.-H.; Cheng A.-L.; Yang J.C.-H.; Lai M.-S.
臺大學術典藏 2020-04-10T12:16:03Z The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia Kuo H.-Y.;Lin Z.-Z.;Kuo R.;Shau W.-Y.;Lai C.-L.;Yang Y.-Y.;Yu-Yun Shao;Hsu C.;Cheng W.-F.;Cheng A.-L.;Yang J.C.H.;Lai M.-S.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; YU-YUN SHAO; Hsu C.; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S.
臺大學術典藏 2020-04-10T12:16:03Z Integrated stable isotope labeling by amino acids in cell culture (SILAC) and isobaric tags for relative and absolute quantitation (iTRAQ) quantitative proteomic analysis identifies galectin-1 as a potential biomarker for predicting sorafenib resistance in liver cancer Ho W.-C.; Tsai M.-H.; Feng W.-C.; Chow L.-P.; Hsu C.-H.; YU-YUN SHAO; Yeh C.-C.;Hsu C.-H.;Yu-Yun Shao;Ho W.-C.;Tsai M.-H.;Feng W.-C.;Chow L.-P.; Yeh C.-C.
臺大學術典藏 2020-04-10T12:16:03Z Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials Chan S.-Y.; Shau W.-Y.; YU-YUN SHAO; Yu-Yun Shao;Shau W.-Y.;Chan S.-Y.;Lu L.-C.;Hsu C.-H.;Cheng A.-L.; Lu L.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2020-04-10T12:16:02Z Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there? Yu-Yun Shao;Hsu C.-H.;Cheng A.-L.; YU-YUN SHAO; Hsu C.-H.; Cheng A.-L.

显示项目 41-65 / 113 (共5页)
<< < 1 2 3 4 5 > >>
每页显示[10|25|50]项目